SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with ...

In cancer-associated cachexia, elevated TNF-α and IL-6 exacerbate muscle and fat loss by regulating multiple metabolic signaling pathways, which could be ameliorated by Z526's suppression of NF-κB ...

Fortive Corporation ("Fortive") today announced that its Board of Directors has appointed Sharmistha "Shar" Dubey as the Chair of the Board. Ms. Dubey succeeds Alan G. Spoon who has notified the Board ...

Lenovo is proud to announce that it has achieved all six Microsoft Solutions Partner Designations under the Microsoft AI Cloud Partner Program. This recognition underscores Lenovo's technical ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

The following is a summary of “Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease,” published ...

Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Scientists studying an aggressive cancer that affects thousands of dogs annually have uncovered a genetic signature that ...

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

In a report released today, Roger Song from Jefferies maintained a Buy rating on Kura Oncology (KURA – Research Report), with a price target of ...